

Product datasheet for TL302937V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

NMNAT1 Human shRNA Lentiviral Particle (Locus ID 64802)

Product data:

Product Type: shRNA Lentiviral Particles

Product Name: NMNAT1 Human shRNA Lentiviral Particle (Locus ID 64802)

Locus ID: 64802

Synonyms: LCA9; NMNAT; PNAT1; SHILCA

Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: NMNAT1 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1

scramble control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 001297778, NM 001297779, NM 022787, NM 022787.1, NM 022787.2, NM 022787.3,

NM 001297779.1, NM 001297778.1, BC014943, BC014943.1, BC032483, NM 022787.4,

NM 001297779.2

UniProt ID: Q9HAN9

Summary: This gene encodes an enzyme which catalyzes a key step in the biosynthesis of nicotinamide

adenine dinucleotide (NAD). The encoded enzyme is one of several nicotinamide nucleotide adenylyltransferases, and is specifically localized to the cell nucleus. Activity of this protein leads to the activation of a nuclear deacetylase that functions in the protection of damaged neurons. Mutations in this gene have been associated with Leber congenital amaurosis 9. Alternative splicing results in multiple transcript variants. Pseudogenes of this gene are

located on chromosomes 1, 3, 4, 14, and 15. [provided by RefSeq, Jul 2014]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.







Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).